Kinfo
Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSCNASDAQHealthcare·US · USD
$2.41
+0.09 (+3.88%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap434.66M USD
Enterprise value331.65M USD
Trailing P/E-17.21
Forward P/E-5.07
PEG ratio0.15
Price / sales3.98
Price / book1.58
Profitability
Gross margin0.00%
Operating margin-9.62%
Profit margin0.00%
Return on assets-22.28%
Return on equity-42.67%
Income (TTM)
Revenue109.16M USD
Gross profit-86.19M USD
EBITDA9.36M USD
Net income-107.78M USD
Diluted EPS-$1.14
Rev. growth (YoY)0.00%
Balance sheet
Total cash134.80M USD
Total debt48.02M USD
Debt / equity18.14
Current ratio10.25
Book value / share$1.47
Cash flow (TTM)
Operating cash flow-94.52M USD
Levered free cash flow-53.63M USD
Shares & price
Shares outstanding180.10M
Float97.86M
Held by institutions78.57%
Beta1.57
50-day MA$2.28
200-day MA$1.56
52-week high$3.04
52-week low$0.44
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-0.17-0.11+35.29%2026-03-12-0.30-0.25+16.67%2025-11-13-0.38-0.32+15.79%2025-11-043.163.01−4.75%2025-10-130.020.03+50.00%
About Century Therapeutics, Inc.

Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision. Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities. In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
Employees
78
Headquarters
Philadelphia, PA, United States

Frequently asked questions about Century Therapeutics, Inc.